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A B S T R A C T
This is the report on the ﬁrst Italian experience with the low glycemic index diet (LGIT) in a group of
children, adolescents and young adults with refractory epileptic encephalopathies. A retrospective chart
review was performed on patients initiating the LGIT in an outpatient setting from 2005 to 2010.
Demographic and clinical information including seizure type, baseline seizure frequency, medications,
blood chemistry, side effects, and anthropometrics were collected. Patients were educated and followed
by a dietician to restrict foods with high glycemic index and to limit total daily carbohydrates to 40–60 g.
Change in seizure frequency was assessed at each 3-month follow-up intervals in the ﬁrst year and then
at each 6-month intervals. Fifteen consecutive patients (13 males and 2 females, aged between 11.3
years and 22 years), almost all affected by generalized cryptogenic or symptomatic refractory epilepsy,
were enrolled in the study. After a mean follow-up period of 14.5  6.5 months (median 12.0; range 1–60
months), 6 patients (40%) had a 75–90% seizure reduction, while seizures decreased by 50% in other 2 (13.3%)
and were unchanged in 7 (46.7%). The diet was discontinued in 4 patients within the ﬁrst 5 months. No
adverse events occurred during the diet. In conclusion, this initial experience conﬁrms that some refractory
patients may improve on the LGIT, even as ﬁrst dietary option.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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The ketogenic diet is no longer the only dietary option for the
treatment of drug-resistant epilepsy.1 Indeed, less restrictive and
more palatable diets such as the low-glycemic index diet (LGIT)2
and the modiﬁed Atkins diet (MAD)3 are currently being tried just
in the aim of avoiding the strict rules imposed by the ketogenic
diet, in which each food is rigidly calculated and weighed as well as
the total amount of the daily calorie intake. As a consequence, the
ketogenic diet is often poorly accepted by older children,
adolescents and adults. Both of these diets are known to be
employed for treating obesity and diabetes type 1 and 2.4,5 Both
require the intake of 60–70% lipids, which is certainly a lower level
compared to 90% in the ketogenic diet, while the rest is made up of
20–30% protein and a 6–10% carbohydrate. Recently, both have
been somewhat modiﬁed for the treatment of epileptic patients. In
particular, the LGIT allows 10% of carbohydrate intake, but with a* Corresponding author at: Clinic of Child Neuropsychiatry, University of Salerno,
S. Leonardo Hospital, 84100 Salerno, Italy. Tel.: +089 756045; fax: +089 8454352.
E-mail address: gcoppola@unisa.it (G. Coppola).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.03.008low-glycemic index.6 It is noted that a low GI food causes a minor
elevation of postprandial blood glucose levels, which may be
advantageous for the recurrence of the seizures. Pfeiffer and
Thiele2 ﬁrst reported the use of the LGIT in 20 patients with
refractory epilepsy, with signiﬁcant reduction in seizures in
approximately 50% of cases. More recently the same authors
reported their experience on a broader case study.7
The purpose of this paper is to report on the ﬁrst Italian
experience with this diet in a group of children, adolescents and
young adults with refractory epileptic encephalopathies.
2. Materials and methods
Patients enrolled in this study were followed at the pediatric
epilepsy service of the Clinic of Child and Adolescent Neuropsy-
chiatry of the Second University of Naples, from 2005 to 2010.
Patients were recruited according to the following inclusion
criteria: (1) generalized or focal seizures, refractory to at least three
consecutive anticonvulsant drugs, with at least four seizures per
month over the last 3 months; (2) age of 3 years and more; (3)
informed consent to follow the diet. Exclusion criteria were: (1)
presence of progressive or metabolic neurological or systemicvier Ltd. All rights reserved.
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parents/caregivers. In each patient, before the diet, dietary survey
was carried out with the assessment of the total daily energy
intake and evaluation of the favorite food in the last 3 months. In
addition, each patient underwent the following tests: haemato-
chemical proﬁle including complete blood count, transaminases,
blood glucose, blood urea nitrogen, total serum proteins, serum
iron, lipid proﬁle (total cholesterol, HDL and LDL, triglycerides),
alkaline phosphatase, calcium, phosphorus, urinalysis, and blood
levels of concomitant anticonvulsant drugs. Echoes of the heart,
kidney and liver were then performed in each patient as well as an
EEG recording during wakefulness and sleep and the assessment of
body mass index (BMI). Frequency and type of seizures in the last 3
months were evaluated, using a diary to be completed by parents/
caregivers. Magnetic resonance imaging study was performed in
all patients. The follow-up was carried out by clinical examination
every 3 months during the ﬁrst year of dieting and then every 6
months, with the evaluation of the frequency and type of seizures,
compliance to the diet and any side effects, by examining a clinical
diary to be completed by parents. In addition, each patient was
followed for all questions and concerns about diet by a team of
dieticians. The same exams as before the diet were then carried out
in the follow-up visits, including urine ketostix and body mass
index. The EEG recording was performed every 6 months, and
echoes of the heart, kidney and liver every 12 months. Response to
treatment was evaluated by comparing the frequency of countable
seizures at baseline (4 weeks before LGIT therapy) with the
frequency in the last 4 weeks of observation. Efﬁcacy was rated
using the following categories: (1) seizure control (100% seizure
remission); (2) 50–99% reduction in seizure frequency; (3) 25–49%
reduction in seizure frequency; (4) unchanged; (5) worsened when
the seizure rate increased. The Institutional Review Board from ourTable 1
Characteristics of patients, seizure outcome and adverse events on LGIT.
No. of
patient
Age at
diet
onset
(years)
Type of
epilepsy
Type of
seizure
Duration of
epilepsy
< LGIT
(years)
CT/MRI 
1 4 SEE IS and motor
focal seizures
8 Cortical and subcortic
brain atrophy
2 18 LGS Absences and
drop attacks
9 Cerebellar vermis
hypoplasia
3 6 LGS Tonic, atonic,
drop attacks
6 Normal 
4 13 EPS atonic 13 Hydrocephalus and
migration disorder
5 6 SEE Tonic
asymmetric
7 Cortical and subcortic
brain atrophy
6 3 TSC Spasms and
focal seizures
3.5 TSC 
7 7 Dravet
syndrome
Absences 8 Normal 
8 12 SEE GTCS 9 Partial agenesis of CC
9 18 SEE Tonic 19 Normal 
10 22 SEE GTCS 22 Cortical and subcortic
brain atrophy
11 16 SEE Focal seizures 17 Partial agenesis of CC
diffuse brain ishemia
12 3 LGS GTCS, drop
attacks
3.5 Cortical and subcortic
brain atrophy
13 5 SPE SGTCS 5 Left parietal-occipital
14 16 SPE SGTCS 15 Left temporal lobecto
15 17 SEE Tonic, atonic,
absences
17 Cortical and subcortic
brain atrophy
LGS, Lennox–Gastaut syndrome; TSC, tuberous sclerosis complex; SEE, symptomatic epil
generalized tonic clonic seizures; SGTCS, secondary generalized tonic clonic seizur
carbamazepine; LMT, lamotrigine; LEV, levetiracetam; CLZ, clobazam; CNZ, clonazepam;
vigabatrin; RUF, ruﬁnamide; PHT, phenitoin.University approved the study; no support was received from
pharmaceutical companies.
Each patient was prescribed the LGIT according to the criteria
published by Pfeiffer et al.2 that include a diet consisting of 60–70%
lipids, 20–30% protein and 10% carbohydrates with low glycemic
index (GI < 50). The share of total caloric intake was calculated
based on the ideal weight of each patient.
The diet was added to the baseline anticonvulsant therapy,
which was not changed during follow-up, unless there were
special needs at the discretion of the treating physician. The LGIT
could be the ﬁrst dietary treatment or be administered in patients
who had previously taken the ketogenic diet.
3. Results
Fifteen consecutive patients were enrolled in the study from
2005 to 2010. The group consisted of 13 males and 2 females, aged
between 11.3 years and 22 years (mean 12.4 years), all affected by
generalized or focal, cryptogenic or symptomatic refractory
epilepsy. The epilepsy type was Lennox–Gastaut syndrome in 3,
encephalopathy with spasms and tonic seizures in 8, tuberous
sclerosis complex and infantile spasms in 1, Dravet syndrome in 1
and partial epilepsy in 2. The mean duration of the epilepsy was
10.8  5.9 years (median 9.0; range 3.5–22). The seizure frequency
during the 3 months before the start of the diet was more than 2–5/
day in 12 cases and more than 2/week in 3. Seizures, often
polymorphic in the same patient, were classiﬁed as follows: tonic/
spasms (8), atonic (6), generalized tonic–clonic (3), absences (5),
myoclonic (2), focal with/without secondary generalization (5), and
reﬂex seizures (1). Psychomotor developmental delay was present in
14 of 15 patients (93.3%), being mild in 2, moderate in 5 and severe/
profound in 7. The neurological examination was abnormal in 11 of 15Baseline AEDs Seizure
frequency
< LGIT
Duration of
follow-up
(months)
Seizure
reduction
at follow-up
Adverse
events
al VPA, TPM, CBZ 2/week 60 75–90% N
VPA, LMT 20/month 2 50% N
LEV, CLZ,
VPA, CBZ
2–3/day 24 Unchanged N
ZNS, VPA, CNZ 5–10/day 1 Unchanged N
al PB, CNZ >50/day 24 75–90% N
OXC, ACZ, VGB 1–2/day 12 75–90% N
ZNS, TPM,
VPA, CNZ
10–20/day 24 75% N
 PB, VPA,
LEV, CLZ
10/day 1 75% N
PB 2–3/day 12 75% N
al VPA, TPM 2–4/day 5 50% N
 and VGB, CBZ, LEV 20/day 12 Unchanged N
al CNZ, VPA,
CBZ, RUF
2–4/day 24 Unchanged N
 atrophy CBZ, CLZ, PB 2–5/day 12 Unchanged N
my CBZ, VPA 6–7/week 3 Unchanged N
al VPA, VGB,
CNZ, PHT
7–8/month 1 Unchanged N
eptic encephalopathy; SPE, symptomatic partial epilepsy; IS, infantile spasm; GTCS,
es; CC, corpus callosum; N, none; VPA, valproic acid; TPM, topiramate; CBZ,
 ZNS, zonisamide; PB, phenobarbital; OXC, oxcarbazepine; ACZ, acetazolamide; VGB,
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Fig. 1. Relationship between outcome and LGIT as ﬁrst treatment or after ketogenic
diet.
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in 2. Mental retardation was mild in 2 patients, moderate in 6, and
profound in 7. Brain MRI showed a normal ﬁnding in 4 cases and
abnormal in 11 (cerebral atrophy, 4; migration disorders/brain
malformation, 3, TSC, 1, periventricular leukomalacia, 1, partial
agenesis of the corpus callosum, 1; left temporal lobectomy, 1). The
baseline anti-epileptic therapy consisted of the following drugs, as
alone or in combination: valproic acid (10), carbamazepine (6),
clonazepam (5), phenobarbital (4), topiramate, levetiracetam,
clonazepam, vigabatrin (3), zonisamide (2), lamotrigine (1), ruﬁna-
mide, acetazolamide, oxcarbazepine, phenytoin (1). A single drug was
taken by 1 patient, two drugs by 4, three drugs by 5, and more than
three by 5.
Eight patients (53%) have taken the LGIT diet as the ﬁrst dietary
treatment, while in the other seven patients the average interval
between the end of the ketogenic diet and the beginning of the
LGIT was 24.1  33.6 months (median 10.0, range 3–96). After a
mean follow-up period of 14.5  15.6 months (median 12.0, range 1–
60 months), 6 patients (40%) had a 75–90% seizure reduction in
countable seizures, while seizures decreased by 50% in other 2 (13.3%)
and were unchanged in 7 (46.7%) (Table 1). The diet was discontinued
in 3 patients within the ﬁrst 4 weeks due to poor compliance and in
another patient after 5 months because of poor compliance despite a
signiﬁcant reduction of seizures. No adverse events occurred during
the diet, and there were no metabolic changes such as the appearance
of ketone bodies or changes in blood glycemic level and lipidogram.
The ultrasounds of the kidney and heart at the time of follow-up were
normal in all patients. Fig. 1 shows the reduction in seizure frequency
in patients treated with LGIT given as ﬁrst diet or after the ketogenic
diet.
4. Discussion
In our experience the LGIT was effective in reducing seizure
frequency in a number of patients with drug resistant epilepsy,
being well accepted and tolerated for prolonged periods. Among
the patients who received the diet with a reduction of >50% of the
seizures, there were ﬁve with multifocal epileptic encephalopathy,
one with Lennox-Gastaut syndrome and one with Dravet
syndrome. Another patient with tuberous sclerosis complex and
focal-onset spasms, had a 90% seizure decrease; he also showed
improved behavior and sleep quality. Our experience is somewhat
similar to that reported by Pfeiffer and Thiele,2 who found a greater
than 90% reduction in seizure frequency in half of 20 patients
treated with this regimen. More recently, Muzykewicz et al.7 have
published retrospective data on a larger series of 76 drug-resistant
epilepsy children treated with LGIT. The 1-year follow-up
conﬁrmed a >50% seizure reduction in 66% of this cohort.In our series, there were no substantial changes in blood glucose
level, and only transient appearance of ketone bodies in some
patients. Increased efﬁcacy was somewhat correlated with lower
serum glucose levels. Compliance was low in 4 of 15 patients
(26.7%), aged between 13 and 22 years, like in 24% of the cases
reported by Muzykewicz et al.7
The LGIT was the ﬁrst dietary treatment for 8 of our patients
(53%), as well as in the series by Pfeiffer and Thiele2; of note is that
three of these patients developed poor compliance very early,
while the other ﬁve had a satisfactory response for at least 1 year.
Of the patients treated with the ketogenic diet prior to the LGIT,
the patients 5 and 7 beneﬁted from the ketogenic diet for 18
months. Because of persistent vomiting and/or constipation, they
both were switched to the LGIT for 2 years with good results and no
side effects. The patient 1, after 15 months on KD with more than
50% seizure decrease, discontinued it due to loss of efﬁcacy; he was
then shifted to the LGIT with a 50% seizure reduction persisting for
5 years.
The patient 3 was on the ketogenic diet from the age of 4 years
with adequate response for 1 year; he then discontinued the diet
due to lack of compliance. He afterwards followed the LGIT for 2
years, achieving poor results; it is worth stressing the severe
clinical condition in this case.
The patient 9 was on the ketogenic diet for about 8 years,
discontinuing it at 12 years of age in the absence of seizures; after
an interval of 6 years, due to the reappearance of tonic seizures, the
LGIT was started leading to a 70% seizure reduction. The patient 4
showed poor results and compliance with the KD and LGIT,
discontinuing them within a few months.
Finally, the patient 8, after taking the ketogenic diet with a more
than 90% seizure reduction, had to discontinue it because of
increased level of triglicerides; a new attempt with the ketogenic
diet led to the same adverse event and the KD had to be stopped
again. Once on the LGIT, there was a seizure reduction of 75%, with
no side effects.
In conclusion, this initial experience with the LGIT conﬁrms
what reported by the group of Pfeiffer and Thiele2 and Muzykewicz
et al.,7 albeit with less exciting results. The LGIT is a diet that can be
beneﬁcial to some patients with refractory epilepsy syndromes
including epileptic encephalopathies with polymorphic seizures
and Lennox–Gastaut syndrome. Compliance is certainly better
than with the ketogenic diet,2 although about one-fourth of
patients do not accept even this type of diet.
The LGIT may rightly be considered, along with the modiﬁed
Atkins diet, a diet for epilepsy alternative to the more restrictive
ketogenic diet, to be offered to patients over the age of 2–3 years, as
ﬁrst dietary treatment in combination with the anti-epileptic
therapy.
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